Related Experiment Videos
Expression of CD66a in multiple myeloma
Yukihiko Satoh1, Toshiaki Hayashi, Tohru Takahashi
1First Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.
Journal of Clinical Laboratory Analysis
|April 12, 2002
Summary
CD66a is frequently expressed in multiple myeloma cells. This study investigated CD66a expression in various B-cell malignancies, finding high prevalence in multiple myeloma and related disorders.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- CD66a, a member of the carcinoembryonic antigen family, is implicated in cell adhesion and growth regulation.
- Its expression in multiple myeloma, a plasma cell malignancy, requires further investigation.
Purpose of the Study:
- To determine the expression frequency of CD66a in multiple myeloma and related hematological malignancies.
- To assess the correlation of CD66a expression with conventional myeloma cell markers.
Main Methods:
- Utilized monoclonal antibody (mAb) TS135 to detect CD66a expression in myeloma cell lines and clinical bone marrow specimens.
- Employed indirect immunofluorescence assay and two-dimensional flow cytometry.
- Examined CD66a alongside PCA-1, CD38, and CD56 markers.
Main Results:
- CD66a was detected in three myeloma cell lines and an IgM-producing B-cell line.
- 86% (18 out of 21) of clinical bone marrow specimens, including multiple myeloma, primary macroglobulinemia, and chronic lymphoproliferation, were CD66a positive.
- PCA-1 demonstrated the highest correlation with CD66a expression among conventional markers.
Conclusions:
- CD66a is expressed in multiple myeloma with high frequency.
- CD66a represents a potential marker for B-cell malignancies, including multiple myeloma.